Insiders · APLS

Pascal Deschatelets

Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS)

Pascal Deschatelets has filed 55 insider reports with the SEC since February 2021, as chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS). In the last 12 months Pascal Deschatelets sold $198K of stock on the open market. The latest filing, on May 14, 2026, reports grant or award, sale back to the company and tender of shares in a change of control at Apellis Pharmaceuticals, Inc. (APLS).

Filings
55
Companies
1
Bought on market
None
Sold on market
$25.5M

Companies where Pascal Deschatelets is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Apellis Pharmaceuticals, Inc. logo
APLS
Apellis Pharmaceuticals, Inc.
Chief Scientific Officer0$25.5MMay 14, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Pascal Deschatelets with

Other insiders at the same companies

Questions about Pascal Deschatelets

What is Pascal Deschatelets's role at Apellis Pharmaceuticals, Inc.?
Pascal Deschatelets reports to the SEC as chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), according to the latest filing on May 14, 2026.
Has Pascal Deschatelets bought or sold stock recently?
The most recent open-market sale was on January 22, 2026: sold 5,928 shares of Apellis Pharmaceuticals, Inc. (APLS) for $129K at an average of $21.77.
How do I get alerts when Pascal Deschatelets files?
Follow Pascal Deschatelets on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Pascal Deschatelets (SEC CIK 0001657720). Totals count each trade once, skipping amendments whose original is on file, from Feb 1, 2021 on. View on SEC EDGAR